clinical trial · NCT06794996
Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities
Vertex Pharmaceuticals Incorporated·phase2·active not recruiting·n = 42
Proteinuric Kidney DiseaseInaxaplin
brief summary
The purpose of the study is to evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in participants with proteinuric APOL1- mediated kidney disease (AMKD).
started
Feb 4, 2025
primary completion
Dec 30, 2026
completion
Dec 30, 2026
last updated
May 5, 2026
official title
A Phase 2b, Open-label Study to Evaluate the Efficacy and Safety of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease With or Without Comorbidities That May Independently Contribute to Chronic Kidney Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol